< Back
Sign In to Follow Application
View All Documents & Correspondence
Login

Heterocyclic Compound That Acts On G12 D Mutant Kras Protein

Abstract: Provided is a compound that is effective as an active ingredient in a therapeutic pharmaceutical composition for pancreatic cancer. Having studied compounds that are effective as active ingredients in a therapeutic pharmaceutical composition for pancreatic cancer, the inventors found that the heterocyclic compound shown in formula (I) has excellent degradation-inducing action in the G12D mutant KRAS protein and/or inhibitory activity for G12D mutant KRAS and can be used as a therapeutic drug for pancreatic cancer, and thus completed the present invention. The heterocyclic compound according to the present invention or salts thereof can be used as a therapeutic drug for pancreatic cancer.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
14 February 2025
Publication Number
08/2025
Publication Type
INA
Invention Field
CHEMICAL
Status
Email
Parent Application

Applicants

ASTELLAS PHARMA INC.
5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

Inventors

1. YOSHINARI, Tomohiro
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
2. WATANABE, Hideyuki
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
3. ISHIOKA, Hiroki
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
4. KAWAMINAMI, Eiji
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
5. KAWAGUCHI, Kenichi
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
6. TAKAHASHI, Fumie
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
7. KAMIKUBO, Takashi
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
8. IMAIZUMI, Tomoyoshi
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
9. MORIKAWA, Takahiro
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
10. HAMAGUCHI, Hisao
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
11. KURAMOTO, Kazuyuki
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
12. INAMI, Hiroshi
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
13. NAGASHIMA, Takeyuki
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
14. INAMURA, Kohei
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411

Specification

Documents

Application Documents

# Name Date
1 202547012835-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [14-02-2025(online)].pdf 2025-02-14
2 202547012835-STATEMENT OF UNDERTAKING (FORM 3) [14-02-2025(online)].pdf 2025-02-14
3 202547012835-REQUEST FOR EXAMINATION (FORM-18) [14-02-2025(online)].pdf 2025-02-14
4 202547012835-PROOF OF RIGHT [14-02-2025(online)].pdf 2025-02-14
5 202547012835-PRIORITY DOCUMENTS [14-02-2025(online)].pdf 2025-02-14
6 202547012835-FORM 18 [14-02-2025(online)].pdf 2025-02-14
7 202547012835-FORM 1 [14-02-2025(online)].pdf 2025-02-14
8 202547012835-DECLARATION OF INVENTORSHIP (FORM 5) [14-02-2025(online)].pdf 2025-02-14
9 202547012835-COMPLETE SPECIFICATION [14-02-2025(online)].pdf 2025-02-14
10 202547012835-FORM-26 [17-02-2025(online)].pdf 2025-02-17
11 202547012835-RELEVANT DOCUMENTS [03-03-2025(online)].pdf 2025-03-03
12 202547012835-MARKED COPIES OF AMENDEMENTS [03-03-2025(online)].pdf 2025-03-03
13 202547012835-FORM 13 [03-03-2025(online)].pdf 2025-03-03
14 202547012835-Annexure [03-03-2025(online)].pdf 2025-03-03
15 202547012835-AMMENDED DOCUMENTS [03-03-2025(online)].pdf 2025-03-03
16 202547012835-FORM 3 [23-07-2025(online)].pdf 2025-07-23